Table 2.
Effectiveness for acute pancreatitis with protease inhibitors
| Outcomes | No. of studies |
Pooled risk difference |
NNT |
Heterogeneity |
Statistical method by effect model | Quality of a body of evidence | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Value |
95%CI |
Value |
95%CI | I 2 value(%) | ||||||
| Lower | Upper | NNTB | NNTH | |||||||
| Death |
17 |
-0.02 |
-0.05 |
0.01 |
74.8 |
|
NNTH 62.4 to ∞ to NNTB 23.4 |
0 |
M-H |
low |
| High quality studies |
6 |
-0.02 |
-0.06 |
0.02 |
|
624.6 |
NNTH 24.6 to ∞ to NNTB 26.7 |
34.1 |
M-H |
|
| Aprotinin |
11 |
-0.01 |
-0.05 |
0.02 |
89.3 |
|
NNTH 38.8 to ∞ to NNTB 20.8 |
0 |
M-H |
|
| Gabexate mesilate |
6 |
-0.02 |
-0.07 |
0.03 |
54.3 |
|
NNTH 33.3 to ∞ to NNTB 14.9 |
31.1 |
M-H |
|
| Daily dosage >900 mg of GM |
5 |
-0.02 |
-0.09 |
0.04 |
55.2 |
|
NNTH 8.3 to ∞ to NNTB 14.C |
47.0 |
M-H |
|
| Daily dosage >1500 mg of GM |
2 |
-0.09 |
-0.33 |
0.15 |
33.6 |
|
NNTH 17.8 to ∞ to NNTB 8.6 |
79.0 |
D-L |
|
| Mild pancreatitis |
7 |
0.00 |
-0.03 |
0.04 |
|
177.5 |
NNTH 24.5 to ∞ to NNTB 33.9 |
0 |
M-H |
|
| Moderate to severe pancreatitis |
10 |
-0.03 |
-0.07 |
0.01 |
|
1604 |
NNTH 23.0 to ∞ to NNTB 23.7 |
19.7 |
M-H |
|
| Severe pancreatitis |
2 |
-0.19 |
-031 |
-0.08 |
5.2 |
|
3.2 to 12.7 |
0 |
M-H |
|
| With sponsor |
9 |
-0.02 |
-0.06 |
0.02 |
67.0 |
|
NNTH 43.0 to ∞ to NNTB 18.8 |
15.0 |
M-H |
|
| Without sponsor |
8 |
-0.02 |
-0.06 |
0.03 |
68.4 |
|
NNTH 31.9 to ∞ to NNTB 16.5 |
0 |
M-H |
|
| Abdominal pain |
2 |
-0.26 |
-0.40 |
-0.13 |
3.9 |
2.5 to 9.6 |
85.0 |
D-L |
|
very low |
| High quality study |
1 |
-0.14 |
-0.32 |
0.03 |
6.9 |
|
NNTH 30.1 to ∞ to NNTB 3.1 |
Uncalculatable |
M-H |
|
| Pseudocyst formation |
5 |
-0.00 |
-0.05 |
0.03 |
298.6 |
|
NNTH 27.3 to ∞ to NNTB 23.1 |
0 |
M-H |
low |
| Intra-abdominal abscess formation |
4 |
-0.01 |
-0.04 |
0.02 |
113.2 |
|
NNTH 65.3 to ∞ to NNTB 30.3 |
0 |
M-H |
low |
| Surgical intervention |
3 |
-0.08 |
-0.17 |
-0.00 |
11.8 |
|
6.0 to 443.8 |
60.5 |
D0L |
very low |
| High quality study |
1 |
0.00 |
-0.10 |
0.11 |
|
225.8 |
NNTH 8.9 to ∞ to NNTB 9.7 |
Uncalculatable |
M-H |
|
| Bowel obstruction |
3 |
-0.06 |
-0.12 |
-0.00 |
6.3 |
|
4.0 to 14.5 |
58.8 |
D-L |
very low |
| High quality study |
1 |
-0.03 |
-0.08 |
0.02 |
33.9 |
|
NNTH 44.2 to ∞ to NNTB 12.3 |
Uncalculatable |
M-H |
|
| Any major complications | 5 | -0.01 | -0.08 | 0.06 | 76.4 | NNTH 15.7 to ∞ to NNTB 11.1 | 0 | M-H | low | |
NNT number needed to treat; NNTB number needed to treat benefit; NNTH number needed to treat harm; CI confidence intervals; M-H mantel-haenszel; D-L dersimonian-laird; GM, gabexate mesilate.